SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ELMS STEVE

(Last)

(First)

(Middle)

888 7TH AVENUE

30TH FLOOR

(Street)

NEW YORK

10106

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/14/2015

3. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	703,092	I	By Seachaid Pharmaceuticals, LLC.⁽¹⁾⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Convertible Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	351,518	$0.00	I	by Aisling Capital II, L.P.⁽²⁾⁽⁴⁾

Explanation of Responses:

1. Shares of common stock, par value $0.0001 per share (the "Common Shares") of Cidara Therapeutics, Inc. (the "Issuer") are held directly by Seachaid Pharmaceuticals, LLC. ("Seachaid").

2. Mr. Steve Elms is the chief executive officer of Seachaid and a member of the investment committee of Aisling Capital II, L.P. ("Aisling") as well as one of the managing members of Aisling Capital Partners LLC ("Aisling Partners"). The investment committee of Aisling holds sole voting and dispositive power over the Common Shares held by Seachaid and the Preferred Shares held by Aisling. Aisling is a majority-owner of Seachaid. Aisling Capital Partners LP ("Aisling GP") is the general partner of Aisling and Aisling Partners is the general partner of Aisling GP. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling and Seachaid. Mr. Elms disclaims beneficial ownership of the Common Shares and Preferred Shares, except to the extent of his pecuniary interest.

3. Shares of preferred stock, par value $0.0001 per share (the "Preferred Shares") are convertible at any time, at the holder's election, and have no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Shares will automatically convert into Common Shares on a 25.4-to-1 basis.

4. The Preferred Shares are directly held by Aisling.

Remarks:

	/s/ Steve Elms	04/14/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.